To hear about similar clinical trials, please enter your email below
Trial Title:
What is Optimal Post-operative Prophylactic Therapy in Irradiated Breasts Undergoing Repeat Surgery
NCT ID:
NCT05823467
Condition:
Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Trimethoprim
Sulfamethoxazole
Conditions: Keywords:
radiation
breast conservation surgery
recurrent breast cancer
wound VAC
postoperative antibiotics
post operative wound complications
repeat breast surgery
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Intervention model description:
This study will randomize patients to three arms - patients will either be randomized to
post operative antibiotic arm (1 week), post operative wound VAC arm (1 week), or no
intervention.
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
TMP-SMX DS
Description:
Oral Antibiotic - used to treat post operative wound infections.
Arm group label:
Post operative Antibiotic
Other name:
Trimethoprim / Sulfamethoxazole
Intervention type:
Device
Intervention name:
ciNPT dressing
Description:
Negative pressure wound VAC placed on incision post operatively.
Arm group label:
Post operative Wound VAC
Other name:
PICO dressing
Summary:
This study will look at whether females who have previously had breast surgery and
radiation and are undergoing repeat breast surgery require any post operative
interventions. The reason the investigators are conducting this study is because females
who have undergone breast radiation are at higher risk of wound complications following
breast surgery. The investigators will randomize recruited female participants into three
arms, one which is post operative antibiotics for one week, one which is a wound VAC, and
one which is no intervention. The investigators goal is to identify whether these
patients will require any postoperative interventions.
Detailed description:
Background:
The 10-year local recurrence rate for breast cancer following breast conserving surgery
(BCS) and radiation therapy (RT) is estimated around 19% for which the standard of care
is completion mastectomy. This represents a growing population of patients with prior
irradiation undergoing repeat oncologic surgery. Patients undergoing surgery after RT
have been shown to be at higher risk for wound complications such as surgical site
infection (SSI), dehiscence, and skin necrosis. The average rate of SSI following major
breast surgery is estimated at 5%, whereas it has been reported over 30% in irradiated
patients. However, the data remains sparse dedicated to mitigating early wound
complications in this patient population with guidelines or recommendations that exist
for prophylactic measures.
A retrospectively review analyzed SSI rate in patients undergoing mastectomy without
reconstruction and found a statistically significant reduction in SSI rate with
post-operative antibiotics in the subset of patients with previous RT (30.8% to 3.6%). In
another study of a prospectively followed cohort of high-risk patients undergoing breast
cancer surgery, a subset of whom had previous RT, these patients were found to have a
significant reduction from 45% to 4% for all wound complications (no reported SSI) with
closed incision negative pressure wound therapy (ciNPT) and post-operative antibiotics.
Therefore, the investigators hypothesize that patients with prior BCS and RT undergoing
repeat oncologic breast surgery would benefit from post-operative prophylactic therapy to
reduce early wound complications. Retrospective analyses and prospective cohort studies
have demonstrated potential benefit; however, a high quality RCT is warranted to analyze
our research question.
Study Design:
The investigator's primary objective will be to evaluate the effect of a 7-day course of
TMP-SMX DS and 7-day application of ciNPT dressing (PICO) on the rate of early wound
complications in this patient population. This study will be designed as an unblinded
block randomized controlled trial with three arms: 1) standard of care 2) post-operative
antibiotics 3) ciNPT. Participants will be recruited by surgeons at the Meadowlark and
Sturgeon surgical clinics. Data will be collected via paper forms or Connect Care at 1-2
week and 4-6 week post-operative visits. The primary outcome measure will be wound
complications (SSI, dehiscence, skin necrosis). Secondary outcomes will include adverse
effects of antibiotics or ciNPT therapy, and other post-operative complications (extended
antibiotic therapy, re-operation, admission to hospital).
Impact:
The investigators hope the results of this trial will demonstrate benefit of prophylactic
antibiotics and/or ciNPT to decrease wound complications in this patient population. This
will have the potential to create recommendations for a post-operative prophylactic
regimen to inform future guidelines and practice in oncologic breast surgery.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Female
- > 18 years of age
- Previous breast surgery and ipsilateral breast irradiation
- Requiring repeat breast surgery
Exclusion Criteria:
- Male
- <18 years of age,
- Currently on antibiotic therapy for other indications
- Known hypersensitivity to trimethoprim or sulfonamides,
- History of drug-induced immune thrombocytopenia with use of trimethoprim and/or
sulfonamides
- Documented megaloblastic anemia due to folate deficiency
- Currently pregnant or breastfeeding, and
- Marked hepatic damage
- Severe renal insufficiency
- Severe sensitivity or allergy to silicone adhesive
Gender:
Female
Gender based:
Yes
Gender description:
Patients with Breast Cancer - male breast cancer will present a confounding variable
Minimum age:
18 Years
Maximum age:
99 Years
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Meadowlark Health Centre
Address:
City:
Edmonton
Zip:
T5R 5W9
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Azadeh Rajaee, MD
Email:
rajaee@ualberta.ca
Facility:
Name:
St Thomas Surgical Clinic
Address:
City:
St. Albert
Zip:
T8N 7J6
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Azadeh Rajaee, MD
Email:
rajaee@ualberta.ca
Start date:
June 26, 2023
Completion date:
December 31, 2025
Lead sponsor:
Agency:
University of Alberta
Agency class:
Other
Source:
University of Alberta
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05823467